Robert Bowser received his B.S. degree in biological sciences from Carnegie Mellon University and Ph.D.degree in cell biology from Yale University. He was a Postdoctoral Fellow at the Department of Pathology at Albert Einstein College of Medicine from 1992 to 1994 and since 1994 a faculty member at the Department of Pathology at the University of Pittsburgh School of Medicine. He is the Director of the Center for ALS Research at the University of Pittsburgh (http://www.alsresearchcenter.org/) and a Cofounder of Knopp NeuroSciences, Inc., a biotechnology company focused on generating drug treatments for ALS. Dr. Bowser is also the Director of ALS Research and a Member of the Executive Committee for the Pittsburgh Institute for Neurodegenerative Diseases (PIND). Dr. Bowser's research interests are to determine the molecular and cellular basis of motor neuron cell death in ALS and translate these findings into the clinic. His laboratory was the first to publish a panel of protein biomarkers that can distinguish ALS patients from healthy and other disease control subjects with high accuracy. His lab also searches for biomarkers to monitor ALS disease progression and drug effects in clinical trials. He directs a biomarker validation study for ALS, with 20 participating medical centers from around the USA. He also participates in 2 clinical trials to monitor drug effects in ALS patients using his biomarkers. In addition to this clinical research, Dr. Bowser also explores the role of specific biochemical pathways that regulate motor neuron cell death during ALS to discover new targets for drug therapy.
Biography Updated on 11 November 2009